SCHEMBL206863

SCHEMBL206863

CCCCCCCc1ccc(Nc2nc(-c3ccc(F)cc3)cs2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.60
MAPT P10636 7/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
RAB9A P51151 5/20 0.60
NPC1 O15118 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
NPY5R Q15761 1/20 0.60
POLB P06746 1/20 0.60
KMT2A Q03164 7/20 0.55
MEN1 O00255 6/20 0.55
MAPK1 P28482 2/20 0.55
SPHK2 Q9NRA0 1/20 0.52
SPHK1 Q9NYA1 1/20 0.52
ALDH1A1 P00352 3/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
AMY1A P0DUB6 2/20 0.50
USP2 O75604 1/20 0.50
THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206235 1.00 ALOX5 (0.60) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL205925 0.99 ALOX5 (0.62) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL208369 0.88 ALOX5 (0.60) ALOX5MAPTRAB9ANPC1TDP1
SCHEMBL207687 0.88 ALOX5 (0.60) ALOX5MAPTRAB9ANPC1TDP1
SCHEMBL207407 0.87 ALOX5 (0.62) ALOX5MAPTRAB9ANPC1TDP1
SCHEMBL206462 0.87 ALOX5 (0.46) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL2706493 0.86 MEN1 (0.49) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL204772 0.85 SPHK1 (0.55) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL31126423 0.85 ALOX5 (0.69) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL208684 0.84 ALOX5 (0.60) ALOX5MAPTSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 ALOX5 3410/4885MAPT 2207/4885SMN1; SMN2 3252/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 ALOX5 3410/4885MAPT 2207/4885SMN1; SMN2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.